Adrenal Insufficiency: Symptoms, Cortisol Thresholds, and Treatment Timing

Adrenal insufficiency is a life-threatening hormone deficiency in which the adrenal glands cannot produce enough cortisol, and sometimes too little aldosterone, so the body loses its ability to maintain blood pressure, blood glucose, and electrolyte balance under stress. It affects roughly 5 to 15 people per 100,000 in the United States, and about 60 percent of cases are primary adrenal insufficiency, in which the adrenal cortex itself is damaged. The remaining cases are secondary, driven by pituitary or hypothalamic failure. Without treatment, the condition progresses to adrenal crisis, a shock state with a mortality rate of 6 to 8 percent even with modern emergency care.

What Adrenal Insufficiency Actually Does to the Body

The adrenal cortex produces three hormone classes from three zones: glucocorticoids (cortisol) from the zona fasciculata, mineralocorticoids (aldosterone) from the zona glomerulosa, and androgens from the zona reticularis. Adrenal insufficiency is primarily a cortisol and aldosterone problem. Cortisol is not a stress hormone in the casual sense. It is a permissive hormone that maintains vascular tone, sustains gluconeogenesis during fasting, and suppresses inflammatory overshoot.

In plain terms: cortisol keeps blood vessels responsive to adrenaline and keeps blood sugar available between meals. Lose it, and the body cannot hold blood pressure or fuel the brain during stress.

The mechanism of collapse in primary disease has three arms. First, cortisol loss removes the vascular sensitivity to catecholamines, so vessels dilate and pressure falls. Second, aldosterone loss causes renal sodium wasting, with urine sodium rising above 20 mmol per day and potassium retention pushing serum potassium above 5.0 mmol/L in many patients. Third, loss of cortisol feedback raises ACTH, which co-secretes melanocyte-stimulating hormone and produces the hyperpigmentation that marks primary disease.

Secondary disease spares aldosterone because aldosterone is regulated by the renin-angiotensin system, not ACTH. This single anatomical fact explains why secondary patients rarely show hyperkalemia or hyperpigmentation, and why they can be more insidious. In secondary adrenal insufficiency, the zona glomerulosa keeps working, so sodium and potassium stay near normal while cortisol quietly falls.

Quantified Context: How Common and How Deadly

Primary adrenal insufficiency has a prevalence of roughly 100 to 140 cases per million in European registries, with autoimmune adrenalitis (Addison disease) accounting for 70 to 90 percent of cases in developed countries. Tuberculosis remains a leading cause in regions where it is endemic. Secondary adrenal insufficiency is far more common than older estimates suggested, largely because of chronic exogenous glucocorticoid use. An estimated 1 to 3 percent of adults in the United States take long-term oral steroids, and abrupt withdrawal can unmask suppressed HPA axes in a matter of days.

Adrenal crisis carries an in-hospital mortality of 6 to 8 percent in contemporary series, but it rises above 20 percent when diagnosis is delayed beyond 24 hours. Roughly 8 to 10 percent of patients with known adrenal insufficiency will experience at least one crisis in their lifetime, and precipitating factors are identifiable in 80 percent of episodes: infection, vomiting, surgery, or missed steroid doses.

The threshold that matters most is a morning cortisol below 5 µg/dL, which is strongly suggestive, while a value above 15 µg/dL essentially excludes the diagnosis. Values between 5 and 15 µg/dL require a cosyntropin stimulation test, where a peak cortisol below 18 µg/dL at 30 to 60 minutes confirms insufficiency.

Primary Versus Secondary: The Variations That Change Management

The distinction is not academic. It changes which drugs you need and which emergencies you fear. In primary disease, aldosterone loss means patients need both a glucocorticoid and a mineralocorticoid, typically hydrocortisone plus fludrocortisone at 0.05 to 0.2 mg daily. In secondary disease, fludrocortisone is unnecessary because aldosterone production is intact. Giving it anyway causes hypertension and edema.

Primary patients also face hyponatremia from both sodium loss and cortisol-driven ADH excess, plus hyperkalemia and a mild metabolic acidosis. Secondary patients develop hyponatremia from cortisol deficiency alone but keep potassium normal. That electrolyte pattern is one of the fastest bedside clues.

A third category, tertiary adrenal insufficiency, arises from hypothalamic failure, most often after prolonged exogenous steroid therapy. It behaves like secondary disease but the axis recovers more slowly, sometimes over 6 to 12 months after steroid cessation. The non-obvious edge case: a patient on 5 mg of prednisone daily for two years can have a suppressed axis even though that dose is considered "low." Suppression depends on cumulative exposure and duration, not just dose.

Adrenal Crisis: Timeline and Red Flags

Adrenal crisis is the decompensation event. It typically requires a stressor plus inadequate cortisol reserve. The time course is short and unforgiving.

Red flags that demand immediate parenteral steroid, per the 2016 Endocrine Society clinical practice guideline, include:

• Systolic blood pressure below 100 mmHg with vomiting or abdominal pain
• Serum sodium below 130 mmol/L or potassium above 5.5 mmol/L
• Glucose below 70 mg/dL, especially in a patient with known insufficiency
• Fever above 38.0 °C or any suspected infection
• Inability to keep oral medication down for more than one dose
• Known adrenal insufficiency plus major surgery or trauma

The emergency dose is hydrocortisone 100 mg intravenously, followed by 50 mg every 6 hours or a continuous infusion of 200 mg per 24 hours. Do not delay treatment for a cosyntropin test. Draw the baseline cortisol and ACTH first if access is immediate, but treat within minutes. The stress-dose logic matters: normal adrenal output under severe stress reaches roughly 200 to 300 mg of cortisol equivalent per day, far above replacement levels of 15 to 25 mg daily.

Common Misconceptions, Corrected

The most persistent myth is that adrenal fatigue and adrenal insufficiency are related. They are not. Adrenal insufficiency is a measurable, structural or axis-level failure with objective lab criteria. "Adrenal fatigue" has no validated diagnostic test and does not appear in endocrine guidelines. The two should never be conflated in clinical decision-making.

A second misconception: normal random cortisol excludes the diagnosis. A single afternoon cortisol of 10 µg/dL proves little, because cortisol is pulsatile and diurnal. Only a morning draw before 8 AM or a stimulation test is interpretable.

A third corrected point concerns steroid taper. Many clinicians believe a rapid taper is safe if the patient feels well. In reality, HPA axis recovery lags symptoms by months. A patient can feel fine yet still have a peak cortisol below 18 µg/dL on dynamic testing.

What to Actually Do: Practical Management

Patients with established adrenal insufficiency should carry an emergency kit and a steroid alert card. The kit contains hydrocortisone 100 mg for injection or an equivalent, plus written instructions. Sick-day rules matter more than most patients realize: double the oral dose for fever, triple for vomiting, and switch to injectable steroid if oral intake fails.

Positive actions for daily management include:

• Take hydrocortisone in divided doses, with the largest dose in the morning to mimic the diurnal rhythm.
• Increase the dose for any febrile illness, with the rule of doubling for each degree of fever above 37.5 °C.
• Use injectable hydrocortisone when vomiting prevents oral dosing, and seek emergency care.
• Wear or carry medical identification at all times.
• Review the dose before any surgery, dental procedure, or colonoscopy, since procedural sedation counts as stress.
• Schedule annual reassessment of the axis, especially after stopping long-term steroids.

For secondary and tertiary cases, the recovery window after stopping steroids is the key practical fact. Retest the axis at 6 to 12 months with a cosyntropin stimulation test before declaring recovery.

Limitations and the Unsettled Science

Replacement dosing remains imperfect. Standard hydrocortisone at 15 to 25 mg per day does not fully replicate the circadian cortisol curve, and modified-release preparations are available in Europe but not universally approved in the United States. The optimal target for bone and metabolic health is still debated, with some evidence favoring lower total daily doses around 15 mg to reduce osteoporosis risk.

Quality of life in treated patients is measurably lower than in the general population, even with normal lab values. Studies report fatigue and reduced energy in 30 to 50 percent of well-replaced patients, suggesting our replacement is physiologic on paper but not in lived experience. Whether this reflects dose timing, peak-trough mismatch, or an unmeasured hormone deficit is an open question, and the honest answer is that the field does not yet know.

One number ties the whole picture together. A morning cortisol below 5 µg/dL with an elevated ACTH above 2 times the upper limit of normal is diagnostic of primary adrenal insufficiency, and that same patient's risk of crisis within a year is roughly 8 to 10 percent without structured education and a sick-day plan. Diagnosis is straightforward. Keeping the patient out of crisis is where the real work lives.